Course Description

Pharmacopoeias: Basics for Compendial Compliance: FREE WEBINAR

Free Webinar

Course Offering 1707910O2773A
Course ID 2773

In-Person Course

Who Should Attend?
This instructional webinar is designed for individuals with responsibility for ensuring compliance with requirements in the pharmacopoeias, and is broadly applicable to the global bio/pharmaceutical industry, including innovator, generic, biotechnology, consumer-care and related industries.

This webinar will benefit individuals in:
  • Compendial affairs
  • Regulatory affairs/CMC
  • Quality assurance/Quality control
  • Analytical chemistry/Process chemistry
  • R&D/New products/Method development
  • Contract manufacturers/laboratories

Course Description
Compliance with compendial requirements is a legal and regulatory requirement in those countries in which the pharmacopoeia is applicable. This 30-minute, informational webinar is intended to provide an overview of compendial requirements in USP-NF, Ph. Eur., BP, JP, ChP, etc., along with a brief summary of compendial harmonization activities. The webinar concludes with an introduction to compliance with requirements in the pharmacopoeias.

Specific topics include:
  • Setting the Stage: Basic Information
  • General Notices: Some Key Information
  • Compendial Compliance: Introduction
  • Pharmacopoeias:
    – Purpose and Significance
    – Content and Organization
    – Global Perspective: National Pharmacopoeias
    – Compendia Harmonization


Preview the Free Webinar
Maximize Your Learning!
For complete coverage of this subject check our website for:
Pharmacopoeias: A Global Perspective for Compendial Compliance
Course ID #2728

Course Director
J. Mark Wiggins, B.S., M.S.

J. Mark Wiggins is a Director in Regulatory Policy and Compendial Affairs at Merck & Co., Inc., West Point, PA, U.S.A. (known as MSD outside the United States and Canada), with over 30 years’ experience in the pharmaceutical industry. His current responsibilities include preparing and submitting new and revised monographs to the pharmacopoeias for drug products, drug substances, and excipients, as well as reviewing and responding to proposed compendial changes published by pharmacopoeias around the world. Prior to his current position, Mr. Wiggins was responsible for testing and releasing excipients for use in formulation design, scale-up, and clinical supplies. He also has experience in the synthesis and characterization of active pharmaceutical ingredients for use in the treatment of HIV/AIDS, cancer, diabetes, hypercholesterolemia and depression.

Mr. Wiggins has been an active participant in compendial harmonization efforts, serving as PhRMA representative on the ICH Q4B Expert Working Group, and leading several face-to-face meetings with pharmacopoeias on the topic of harmonization. He is also an active contributor to several industry-based compendial discussion groups, and has chaired the US-based PhRMA compendial team, which has important connections with EFPIA, based in the EU. He has been an invited speaker in several international meetings, including presentations on compendial harmonization at the Ph. Eur. workshop on "Quality of Medicines in a Globalized World", and more recently at meetings with the pharmacopoeias and regulators in the US, Europe, India, Japan, Korea, and China.

Mr. Wiggins has authored several papers covering each area of his career. Recent articles include introductions to the concepts of the "Ideal Pharmacopoeia" and "Compendial Globalization", as well as the industry perspective on the pilot project to achieve “Prospective Harmonization” for API monographs. Mr. Wiggins holds degrees in Chemistry from Trinity University and the University of Wisconsin, both in the US.